Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...
Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback